...
首页> 外文期刊>Clinical, Cosmetic and Investigational Dermatology >A placebo-controlled, double-blind clinical trial to evaluate the efficacy of Imedeen? Time Perfection? for improving the appearance of photodamaged skin
【24h】

A placebo-controlled, double-blind clinical trial to evaluate the efficacy of Imedeen? Time Perfection? for improving the appearance of photodamaged skin

机译:一项安慰剂对照的双盲临床试验,用于评估Imedeen ? Time Perfection ?改善光损伤性皮肤外观的功效

获取原文
           

摘要

Objective: To assess the efficacy of Imedeen Time Perfection for improving the appearance and condition of photoaged skin in healthy women. Methods: This randomized, double-blind, placebo-controlled clinical trial enrolled healthy women, 35–60 years of age, with Fitzpatrick I–III and Glogau II–III skin types and mild-to-moderate facial fine lines/wrinkles. The eligible subjects were randomized to receive two tablets daily of either Imedeen Time Perfection (Imedeen) or a matching placebo for 12 weeks. Efficacy assessments included investigator rating of 16 photoaging parameters (ie, global facial appearance and 15 individual facial parameters and the average of all parameters), instrumentation (ie, ultrasound dermal density, moisture level of the stratum corneum, transepidermal water loss, cutometry), and subjects' self-assessment. Differences in the mean change from baseline to week 12 values on these outcomes were compared between Imedeen and placebo using analysis of variance or a paired t-test. Results: Seventy-four subjects with primarily Fitzpatrick skin type III (78%–79%) and Glogau type III (53%–58%) completed the study (Imedeen: n=36; placebo: n=38). The mean difference in change from baseline to week 12 for global facial assessment significantly favored Imedeen over placebo (?0.52; P =0.0017). Additionally, the mean differences in the average of all facial photoaging parameters (?0.29), mottled hyperpigmentation (?0.25), tactile laxity (?0.24), dullness (?0.47), and tactile roughness (?0.62) significantly favored Imedeen over placebo ( P ≤0.05). Significantly greater increases in ultrasound dermal density (+11% vs +1%; P ≤0.05) and stratum corneum moisturization (+30% vs +6%; P ≤0.05) were also observed for Imedeen than for placebo. There were no significant differences on other instrumental outcomes. Conclusion: The results of this study suggest that Imedeen Time Perfection can positively affect the appearance of photoaged skin, moisturization, and skin density over 12 weeks of treatment.
机译:目的:评估Imedeen Time Perfection改善健康女性光老化皮肤的外观和状况的功效。方法:这项随机,双盲,安慰剂对照的临床试验招募了35至60岁,Fitzpatrick I–III和Glogau II–III皮肤类型和轻度至中度面部细纹/皱纹的健康女性。将符合条件的受试者随机接受每日两片Imedeen Time Perfection(Imedeen)或匹配的安慰剂,持续12周。功效评估包括研究人员对16个光老化参数(例如,整体面部外观和15个单独的面部参数以及所有参数的平均值)的评级,仪器(例如,超声真皮密度,角质层的水分含量,表皮水分流失,皮肤活检),和受试者的自我评估。使用方差分析或配对t检验比较了Imedeen和安慰剂之间这些结果从基线到第12周的平均变化值的差异。结果:74名主要患有Fitzpatrick III型皮肤(78%–79%)和Glogau III型(53%–58%)的受试者完成了研究(Imedeen:n = 36;安慰剂:n = 38)。对于总体面部评估,从基线到第12周的平均变化差异显着使Imedeen优于安慰剂(?0.52; P = 0.0017)。另外,所有面部光老化参数(?0.29),斑驳的色素沉着(?0.25),触觉松弛(?0.24),钝感(?0.47)和触觉粗糙度(?0.62)的平均值的平均差异均明显优于Imedeen优于安慰剂。 (P≤0.05)。与安慰剂相比,Imedeen的超声皮肤密度(+ 11%对+ 1%; P≤0.05)和角质层保湿(+ 30%对+ 6%; P≤0.05)的增加也明显更大。其他工具结果无显着差异。结论:这项研究的结果表明,经过12周的治疗,Imedeen Time Perfection可以积极影响光老化皮肤的外观,保湿和皮肤密度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号